ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global CAR T-Cell Therapy Market Research Report 2026
Published Date: 2026-03-30
|
Report Code: QYRE-Auto-36H13225
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global CAR T Cell Therapy Market Research Report 2023
BUY CHAPTERS

Global CAR T-Cell Therapy Market Research Report 2026

Code: QYRE-Auto-36H13225
Report
2026-03-30
Pages:116
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Bristol–Myers Squibb
J & J
JW Therapeutics
FOSUNKite
CARsgen Therapeutics (Pipeline)
Autolus Therapeutics(Pipeline)
Sorrento Therapeutics(Pipeline)
Mustang Bio(Pipeline)
Bluebird Bio(Pipeline)
Cellectis(Pipeline)
Allogene Therapeutics(Pipeline)
Celyad(Pipeline)
Gilead Sciences
Novartis
J & J

CAR T-Cell Therapy Market Size

The global CAR T-Cell Therapy market was valued at US$ 6685 million in 2025 and is anticipated to reach US$ 33010 million by 2032, at a CAGR of 26.0% from 2026 to 2032.

CAR T-Cell Therapy Market

CAR T-Cell Therapy Market

CAR-T cell therapy (Chimeric Antigen Receptor T-cell therapy) is an innovative form of immunotherapy that involves genetically modifying a patient’s own T cells to express a specific chimeric antigen receptor (CAR) on their surface. This receptor enables the T cells to target and destroy cancer cells effectively. CAR-T therapy has shown significant success in treating hematological malignancies, such as acute lymphoblastic leukemia (ALL) and certain types of lymphomas, and is being explored for its potential applications in solid tumors.
The CAR-T Cell Therapy market is primarily driven by its groundbreaking effectiveness in treating certain types of hematological malignancies, such as acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), particularly in patients who are refractory to standard treatments. The rising incidence of cancer globally and the growing demand for personalized and targeted therapies have further fueled market growth. In addition, advancements in genetic engineering and manufacturing processes are making CAR-T therapies safer, more efficient, and increasingly accessible. The strong support from government initiatives and private investments in oncology research is also accelerating the development of next-generation CAR-T products, expanding their therapeutic potential to include solid tumors.However, the market faces significant challenges, including the high cost of CAR-T therapies, which can exceed hundreds of thousands of dollars per treatment, making it inaccessible to many patients. The complex and time-consuming manufacturing process, which involves extracting and engineering a patient’s T cells, further contributes to these high costs. Additionally, CAR-T therapy is associated with severe side effects, such as cytokine release syndrome (CRS) and neurotoxicity, which require specialized management and can limit its broader adoption. Regulatory hurdles and the need for improved scalability also present obstacles, particularly in developing regions where healthcare infrastructure may be inadequate to support this advanced therapy.
The global top three CAR T-Cell therapy players include Novartis, Gilead Sciences, Bristol-Myers Squibb, with a total market share of more than 99%. The largest player is Gilead Sciences, with a market share of over 50%. North America is the global most important consumer market for CAR T-Cell therapy, with a market share of more than 65%. In terms of type, CD19-targeted CAR cell therapy has a market share of over 90%. In the field of application, the market share of lymphoma exceeds 90%.
This report delivers a comprehensive overview of the global CAR T-Cell Therapy market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding CAR T-Cell Therapy. The CAR T-Cell Therapy market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global CAR T-Cell Therapy market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist CAR T-Cell Therapy manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of CAR T-Cell Therapy Market Report

Report Metric Details
Report Name CAR T-Cell Therapy Market
Accounted market size in 2025 US$ 6685 million
Forecasted market size in 2032 US$ 33010 million
CAGR 26.0%
Base Year 2025
Forecasted years 2026 - 2032
Segment by Type
  • CD19 - Targeted
  • BCMA - Targeted
Segment by Application
  • Lymphoma
  • Multiple Myeloma
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Novartis, Gilead Sciences, Bristol-Myers Squibb, J & J, JW Therapeutics, FOSUNKite, CARsgen Therapeutics (Pipeline), Autolus Therapeutics(Pipeline), Sorrento Therapeutics(Pipeline), Mustang Bio(Pipeline), Bluebird Bio(Pipeline), Cellectis(Pipeline), Allogene Therapeutics(Pipeline), Celyad(Pipeline)
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
  • Chapter 3: Provides a detailed view of the competitive landscape for CAR T-Cell Therapy companies, covering revenue share, development plans, and mergers and acquisitions.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
  • Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
  • Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
  • Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
  • Chapter 12: Key findings and conclusions of the report.

FAQ for this report

How fast is CAR T-Cell Therapy Market growing?

Ans: The CAR T-Cell Therapy Market witnessing a CAGR of 26.0% during the forecast period 2026-2032.

What is the CAR T-Cell Therapy Market size in 2032?

Ans: The CAR T-Cell Therapy Market size in 2032 will be US$ 33010 million.

What is the market share of major companies in CAR T-Cell Therapy Market?

Ans: The global top three CAR T-Cell therapy players include Novartis, Gilead Sciences, Bristol-Myers Squibb, with a total market share of more than 99%.

What is the Gilead Sciences share in CAR T-Cell Therapy Market?

Ans: The largest player is Gilead Sciences, with a market share of over 50%.

What is the CAR T-Cell Therapy Market share by region?

Ans: North America is the global most important consumer market for CAR T-Cell therapy, with a market share of more than 65%.

What is the CAR T-Cell Therapy Market share by type?

Ans: In terms of type, CD19-targeted CAR cell therapy has a market share of over 90%.

What is the CAR T-Cell Therapy Market share by application?

Ans: In the field of application, the market share of lymphoma exceeds 90%.

Who are the main players in the CAR T-Cell Therapy Market report?

Ans: The main players in the CAR T-Cell Therapy Market are Novartis, Gilead Sciences, Bristol-Myers Squibb, J & J, JW Therapeutics, FOSUNKite, CARsgen Therapeutics (Pipeline), Autolus Therapeutics(Pipeline), Sorrento Therapeutics(Pipeline), Mustang Bio(Pipeline), Bluebird Bio(Pipeline), Cellectis(Pipeline), Allogene Therapeutics(Pipeline), Celyad(Pipeline)

What are the Application segmentation covered in the CAR T-Cell Therapy Market report?

Ans: The Applications covered in the CAR T-Cell Therapy Market report are Lymphoma, Multiple Myeloma

What are the Type segmentation covered in the CAR T-Cell Therapy Market report?

Ans: The Types covered in the CAR T-Cell Therapy Market report are CD19 - Targeted, BCMA - Targeted

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global CAR T-Cell Therapy Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 CD19 - Targeted
1.2.3 BCMA - Targeted
1.3 Market by Application
1.3.1 Global CAR T-Cell Therapy Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Lymphoma
1.3.3 Multiple Myeloma
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global CAR T-Cell Therapy Market Perspective (2021–2032)
2.2 Global CAR T-Cell Therapy Growth Trends by Region
2.2.1 Global CAR T-Cell Therapy Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 CAR T-Cell Therapy Historic Market Size by Region (2021–2026)
2.2.3 CAR T-Cell Therapy Forecasted Market Size by Region (2027–2032)
2.3 CAR T-Cell Therapy Market Dynamics
2.3.1 CAR T-Cell Therapy Industry Trends
2.3.2 CAR T-Cell Therapy Market Drivers
2.3.3 CAR T-Cell Therapy Market Challenges
2.3.4 CAR T-Cell Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top CAR T-Cell Therapy Players by Revenue
3.1.1 Global Top CAR T-Cell Therapy Players by Revenue (2021–2026)
3.1.2 Global CAR T-Cell Therapy Revenue Market Share by Players (2021–2026)
3.2 Global Top CAR T-Cell Therapy Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by CAR T-Cell Therapy Revenue
3.4 Global CAR T-Cell Therapy Market Concentration Ratio
3.4.1 Global CAR T-Cell Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by CAR T-Cell Therapy Revenue in 2025
3.5 Global Key Players of CAR T-Cell Therapy Head Offices and Areas Served
3.6 Global Key Players of CAR T-Cell Therapy, Products and Applications
3.7 Global Key Players of CAR T-Cell Therapy, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 CAR T-Cell Therapy Breakdown Data by Type
4.1 Global CAR T-Cell Therapy Historic Market Size by Type (2021–2026)
4.2 Global CAR T-Cell Therapy Forecasted Market Size by Type (2027–2032)
5 CAR T-Cell Therapy Breakdown Data by Application
5.1 Global CAR T-Cell Therapy Historic Market Size by Application (2021–2026)
5.2 Global CAR T-Cell Therapy Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America CAR T-Cell Therapy Market Size (2021–2032)
6.2 North America CAR T-Cell Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America CAR T-Cell Therapy Market Size by Country (2021–2026)
6.4 North America CAR T-Cell Therapy Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe CAR T-Cell Therapy Market Size (2021–2032)
7.2 Europe CAR T-Cell Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe CAR T-Cell Therapy Market Size by Country (2021–2026)
7.4 Europe CAR T-Cell Therapy Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific CAR T-Cell Therapy Market Size (2021–2032)
8.2 Asia-Pacific CAR T-Cell Therapy Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific CAR T-Cell Therapy Market Size by Region (2021–2026)
8.4 Asia-Pacific CAR T-Cell Therapy Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America CAR T-Cell Therapy Market Size (2021–2032)
9.2 Latin America CAR T-Cell Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America CAR T-Cell Therapy Market Size by Country (2021–2026)
9.4 Latin America CAR T-Cell Therapy Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa CAR T-Cell Therapy Market Size (2021–2032)
10.2 Middle East & Africa CAR T-Cell Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa CAR T-Cell Therapy Market Size by Country (2021–2026)
10.4 Middle East & Africa CAR T-Cell Therapy Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis CAR T-Cell Therapy Introduction
11.1.4 Novartis Revenue in CAR T-Cell Therapy Business (2021–2026)
11.1.5 Novartis Recent Development
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Details
11.2.2 Gilead Sciences Business Overview
11.2.3 Gilead Sciences CAR T-Cell Therapy Introduction
11.2.4 Gilead Sciences Revenue in CAR T-Cell Therapy Business (2021–2026)
11.2.5 Gilead Sciences Recent Development
11.3 Bristol-Myers Squibb
11.3.1 Bristol-Myers Squibb Company Details
11.3.2 Bristol-Myers Squibb Business Overview
11.3.3 Bristol-Myers Squibb CAR T-Cell Therapy Introduction
11.3.4 Bristol-Myers Squibb Revenue in CAR T-Cell Therapy Business (2021–2026)
11.3.5 Bristol-Myers Squibb Recent Development
11.4 J & J
11.4.1 J & J Company Details
11.4.2 J & J Business Overview
11.4.3 J & J CAR T-Cell Therapy Introduction
11.4.4 J & J Revenue in CAR T-Cell Therapy Business (2021–2026)
11.4.5 J & J Recent Development
11.5 JW Therapeutics
11.5.1 JW Therapeutics Company Details
11.5.2 JW Therapeutics Business Overview
11.5.3 JW Therapeutics CAR T-Cell Therapy Introduction
11.5.4 JW Therapeutics Revenue in CAR T-Cell Therapy Business (2021–2026)
11.5.5 JW Therapeutics Recent Development
11.6 FOSUNKite
11.6.1 FOSUNKite Company Details
11.6.2 FOSUNKite Business Overview
11.6.3 FOSUNKite CAR T-Cell Therapy Introduction
11.6.4 FOSUNKite Revenue in CAR T-Cell Therapy Business (2021–2026)
11.6.5 FOSUNKite Recent Development
11.7 CARsgen Therapeutics (Pipeline)
11.7.1 CARsgen Therapeutics (Pipeline) Company Details
11.7.2 CARsgen Therapeutics (Pipeline) Business Overview
11.7.3 CARsgen Therapeutics (Pipeline) CAR T-Cell Therapy Introduction
11.7.4 CARsgen Therapeutics (Pipeline) Revenue in CAR T-Cell Therapy Business (2021–2026)
11.7.5 CARsgen Therapeutics (Pipeline) Recent Development
11.8 Autolus Therapeutics(Pipeline)
11.8.1 Autolus Therapeutics(Pipeline) Company Details
11.8.2 Autolus Therapeutics(Pipeline) Business Overview
11.8.3 Autolus Therapeutics(Pipeline) CAR T-Cell Therapy Introduction
11.8.4 Autolus Therapeutics(Pipeline) Revenue in CAR T-Cell Therapy Business (2021–2026)
11.8.5 Autolus Therapeutics(Pipeline) Recent Development
11.9 Sorrento Therapeutics(Pipeline)
11.9.1 Sorrento Therapeutics(Pipeline) Company Details
11.9.2 Sorrento Therapeutics(Pipeline) Business Overview
11.9.3 Sorrento Therapeutics(Pipeline) CAR T-Cell Therapy Introduction
11.9.4 Sorrento Therapeutics(Pipeline) Revenue in CAR T-Cell Therapy Business (2021–2026)
11.9.5 Sorrento Therapeutics(Pipeline) Recent Development
11.10 Mustang Bio(Pipeline)
11.10.1 Mustang Bio(Pipeline) Company Details
11.10.2 Mustang Bio(Pipeline) Business Overview
11.10.3 Mustang Bio(Pipeline) CAR T-Cell Therapy Introduction
11.10.4 Mustang Bio(Pipeline) Revenue in CAR T-Cell Therapy Business (2021–2026)
11.10.5 Mustang Bio(Pipeline) Recent Development
11.11 Bluebird Bio(Pipeline)
11.11.1 Bluebird Bio(Pipeline) Company Details
11.11.2 Bluebird Bio(Pipeline) Business Overview
11.11.3 Bluebird Bio(Pipeline) CAR T-Cell Therapy Introduction
11.11.4 Bluebird Bio(Pipeline) Revenue in CAR T-Cell Therapy Business (2021–2026)
11.11.5 Bluebird Bio(Pipeline) Recent Development
11.12 Cellectis(Pipeline)
11.12.1 Cellectis(Pipeline) Company Details
11.12.2 Cellectis(Pipeline) Business Overview
11.12.3 Cellectis(Pipeline) CAR T-Cell Therapy Introduction
11.12.4 Cellectis(Pipeline) Revenue in CAR T-Cell Therapy Business (2021–2026)
11.12.5 Cellectis(Pipeline) Recent Development
11.13 Allogene Therapeutics(Pipeline)
11.13.1 Allogene Therapeutics(Pipeline) Company Details
11.13.2 Allogene Therapeutics(Pipeline) Business Overview
11.13.3 Allogene Therapeutics(Pipeline) CAR T-Cell Therapy Introduction
11.13.4 Allogene Therapeutics(Pipeline) Revenue in CAR T-Cell Therapy Business (2021–2026)
11.13.5 Allogene Therapeutics(Pipeline) Recent Development
11.14 Celyad(Pipeline)
11.14.1 Celyad(Pipeline) Company Details
11.14.2 Celyad(Pipeline) Business Overview
11.14.3 Celyad(Pipeline) CAR T-Cell Therapy Introduction
11.14.4 Celyad(Pipeline) Revenue in CAR T-Cell Therapy Business (2021–2026)
11.14.5 Celyad(Pipeline) Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Bristol–Myers Squibb
J & J
JW Therapeutics
FOSUNKite
CARsgen Therapeutics (Pipeline)
Autolus Therapeutics(Pipeline)
Sorrento Therapeutics(Pipeline)
Mustang Bio(Pipeline)
Bluebird Bio(Pipeline)
Cellectis(Pipeline)
Allogene Therapeutics(Pipeline)
Celyad(Pipeline)
Gilead Sciences
Novartis
J & J
List of Tables
 Table 1. Global CAR T-Cell Therapy Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
 Table 2. Key Players of CD19 - Targeted
 Table 3. Key Players of BCMA - Targeted
 Table 4. Global CAR T-Cell Therapy Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
 Table 5. Global CAR T-Cell Therapy Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 6. Global CAR T-Cell Therapy Market Size by Region (US$ Million), 2021–2026
 Table 7. Global CAR T-Cell Therapy Market Share by Region (2021–2026)
 Table 8. Global CAR T-Cell Therapy Forecasted Market Size by Region (US$ Million), 2027–2032
 Table 9. Global CAR T-Cell Therapy Market Share by Region (2027–2032)
 Table 10. CAR T-Cell Therapy Market Trends
 Table 11. CAR T-Cell Therapy Market Drivers
 Table 12. CAR T-Cell Therapy Market Challenges
 Table 13. CAR T-Cell Therapy Market Restraints
 Table 14. Global CAR T-Cell Therapy Revenue by Players (US$ Million), 2021–2026
 Table 15. Global CAR T-Cell Therapy Market Share by Players (2021–2026)
 Table 16. Global Top CAR T-Cell Therapy Players by Tier (Tier 1, Tier 2, and Tier 3), based on CAR T-Cell Therapy Revenue, 2025
 Table 17. Ranking of Global Top CAR T-Cell Therapy Companies by Revenue (US$ Million) in 2025
 Table 18. Global 5 Largest Players Market Share by CAR T-Cell Therapy Revenue (CR5 and HHI), 2021–2026
 Table 19. Global Key Players of CAR T-Cell Therapy, Headquarters and Area Served
 Table 20. Global Key Players of CAR T-Cell Therapy, Products and Applications
 Table 21. Global Key Players of CAR T-Cell Therapy, Date of General Availability (GA)
 Table 22. Mergers and Acquisitions, Expansion Plans
 Table 23. Global CAR T-Cell Therapy Market Size by Type (US$ Million), 2021–2026
 Table 24. Global CAR T-Cell Therapy Revenue Market Share by Type (2021–2026)
 Table 25. Global CAR T-Cell Therapy Forecasted Market Size by Type (US$ Million), 2027–2032
 Table 26. Global CAR T-Cell Therapy Revenue Market Share by Type (2027–2032)
 Table 27. Global CAR T-Cell Therapy Market Size by Application (US$ Million), 2021–2026
 Table 28. Global CAR T-Cell Therapy Revenue Market Share by Application (2021–2026)
 Table 29. Global CAR T-Cell Therapy Forecasted Market Size by Application (US$ Million), 2027–2032
 Table 30. Global CAR T-Cell Therapy Revenue Market Share by Application (2027–2032)
 Table 31. North America CAR T-Cell Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 32. North America CAR T-Cell Therapy Market Size by Country (US$ Million), 2021–2026
 Table 33. North America CAR T-Cell Therapy Market Size by Country (US$ Million), 2027–2032
 Table 34. Europe CAR T-Cell Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 35. Europe CAR T-Cell Therapy Market Size by Country (US$ Million), 2021–2026
 Table 36. Europe CAR T-Cell Therapy Market Size by Country (US$ Million), 2027–2032
 Table 37. Asia-Pacific CAR T-Cell Therapy Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 38. Asia-Pacific CAR T-Cell Therapy Market Size by Region (US$ Million), 2021–2026
 Table 39. Asia-Pacific CAR T-Cell Therapy Market Size by Region (US$ Million), 2027–2032
 Table 40. Latin America CAR T-Cell Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 41. Latin America CAR T-Cell Therapy Market Size by Country (US$ Million), 2021–2026
 Table 42. Latin America CAR T-Cell Therapy Market Size by Country (US$ Million), 2027–2032
 Table 43. Middle East & Africa CAR T-Cell Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 44. Middle East & Africa CAR T-Cell Therapy Market Size by Country (US$ Million), 2021–2026
 Table 45. Middle East & Africa CAR T-Cell Therapy Market Size by Country (US$ Million), 2027–2032
 Table 46. Novartis Company Details
 Table 47. Novartis Business Overview
 Table 48. Novartis CAR T-Cell Therapy Product
 Table 49. Novartis Revenue in CAR T-Cell Therapy Business (US$ Million), 2021–2026
 Table 50. Novartis Recent Development
 Table 51. Gilead Sciences Company Details
 Table 52. Gilead Sciences Business Overview
 Table 53. Gilead Sciences CAR T-Cell Therapy Product
 Table 54. Gilead Sciences Revenue in CAR T-Cell Therapy Business (US$ Million), 2021–2026
 Table 55. Gilead Sciences Recent Development
 Table 56. Bristol-Myers Squibb Company Details
 Table 57. Bristol-Myers Squibb Business Overview
 Table 58. Bristol-Myers Squibb CAR T-Cell Therapy Product
 Table 59. Bristol-Myers Squibb Revenue in CAR T-Cell Therapy Business (US$ Million), 2021–2026
 Table 60. Bristol-Myers Squibb Recent Development
 Table 61. J & J Company Details
 Table 62. J & J Business Overview
 Table 63. J & J CAR T-Cell Therapy Product
 Table 64. J & J Revenue in CAR T-Cell Therapy Business (US$ Million), 2021–2026
 Table 65. J & J Recent Development
 Table 66. JW Therapeutics Company Details
 Table 67. JW Therapeutics Business Overview
 Table 68. JW Therapeutics CAR T-Cell Therapy Product
 Table 69. JW Therapeutics Revenue in CAR T-Cell Therapy Business (US$ Million), 2021–2026
 Table 70. JW Therapeutics Recent Development
 Table 71. FOSUNKite Company Details
 Table 72. FOSUNKite Business Overview
 Table 73. FOSUNKite CAR T-Cell Therapy Product
 Table 74. FOSUNKite Revenue in CAR T-Cell Therapy Business (US$ Million), 2021–2026
 Table 75. FOSUNKite Recent Development
 Table 76. CARsgen Therapeutics (Pipeline) Company Details
 Table 77. CARsgen Therapeutics (Pipeline) Business Overview
 Table 78. CARsgen Therapeutics (Pipeline) CAR T-Cell Therapy Product
 Table 79. CARsgen Therapeutics (Pipeline) Revenue in CAR T-Cell Therapy Business (US$ Million), 2021–2026
 Table 80. CARsgen Therapeutics (Pipeline) Recent Development
 Table 81. Autolus Therapeutics(Pipeline) Company Details
 Table 82. Autolus Therapeutics(Pipeline) Business Overview
 Table 83. Autolus Therapeutics(Pipeline) CAR T-Cell Therapy Product
 Table 84. Autolus Therapeutics(Pipeline) Revenue in CAR T-Cell Therapy Business (US$ Million), 2021–2026
 Table 85. Autolus Therapeutics(Pipeline) Recent Development
 Table 86. Sorrento Therapeutics(Pipeline) Company Details
 Table 87. Sorrento Therapeutics(Pipeline) Business Overview
 Table 88. Sorrento Therapeutics(Pipeline) CAR T-Cell Therapy Product
 Table 89. Sorrento Therapeutics(Pipeline) Revenue in CAR T-Cell Therapy Business (US$ Million), 2021–2026
 Table 90. Sorrento Therapeutics(Pipeline) Recent Development
 Table 91. Mustang Bio(Pipeline) Company Details
 Table 92. Mustang Bio(Pipeline) Business Overview
 Table 93. Mustang Bio(Pipeline) CAR T-Cell Therapy Product
 Table 94. Mustang Bio(Pipeline) Revenue in CAR T-Cell Therapy Business (US$ Million), 2021–2026
 Table 95. Mustang Bio(Pipeline) Recent Development
 Table 96. Bluebird Bio(Pipeline) Company Details
 Table 97. Bluebird Bio(Pipeline) Business Overview
 Table 98. Bluebird Bio(Pipeline) CAR T-Cell Therapy Product
 Table 99. Bluebird Bio(Pipeline) Revenue in CAR T-Cell Therapy Business (US$ Million), 2021–2026
 Table 100. Bluebird Bio(Pipeline) Recent Development
 Table 101. Cellectis(Pipeline) Company Details
 Table 102. Cellectis(Pipeline) Business Overview
 Table 103. Cellectis(Pipeline) CAR T-Cell Therapy Product
 Table 104. Cellectis(Pipeline) Revenue in CAR T-Cell Therapy Business (US$ Million), 2021–2026
 Table 105. Cellectis(Pipeline) Recent Development
 Table 106. Allogene Therapeutics(Pipeline) Company Details
 Table 107. Allogene Therapeutics(Pipeline) Business Overview
 Table 108. Allogene Therapeutics(Pipeline) CAR T-Cell Therapy Product
 Table 109. Allogene Therapeutics(Pipeline) Revenue in CAR T-Cell Therapy Business (US$ Million), 2021–2026
 Table 110. Allogene Therapeutics(Pipeline) Recent Development
 Table 111. Celyad(Pipeline) Company Details
 Table 112. Celyad(Pipeline) Business Overview
 Table 113. Celyad(Pipeline) CAR T-Cell Therapy Product
 Table 114. Celyad(Pipeline) Revenue in CAR T-Cell Therapy Business (US$ Million), 2021–2026
 Table 115. Celyad(Pipeline) Recent Development
 Table 116. Research Programs/Design for This Report
 Table 117. Key Data Information from Secondary Sources
 Table 118. Key Data Information from Primary Sources
 Table 119. Authors List of This Report


List of Figures
 Figure 1. CAR T-Cell Therapy Picture
 Figure 2. Global CAR T-Cell Therapy Market Size Comparison by Type (US$ Million), 2021–2032
 Figure 3. Global CAR T-Cell Therapy Market Share by Type: 2025 vs 2032
 Figure 4. CD19 - Targeted Features
 Figure 5. BCMA - Targeted Features
 Figure 6. Global CAR T-Cell Therapy Market Size by Application (US$ Million), 2021–2032
 Figure 7. Global CAR T-Cell Therapy Market Share by Application: 2025 vs 2032
 Figure 8. Lymphoma Case Studies
 Figure 9. Multiple Myeloma Case Studies
 Figure 10. CAR T-Cell Therapy Report Years Considered
 Figure 11. Global CAR T-Cell Therapy Market Size (US$ Million), Year-over-Year: 2021–2032
 Figure 12. Global CAR T-Cell Therapy Market Size, (US$ Million), 2021 vs 2025 vs 2032
 Figure 13. Global CAR T-Cell Therapy Market Share by Region: 2025 vs 2032
 Figure 14. Global CAR T-Cell Therapy Market Share by Players in 2025
 Figure 15. Global CAR T-Cell Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
 Figure 16. The Top 10 and 5 Players Market Share by CAR T-Cell Therapy Revenue in 2025
 Figure 17. North America CAR T-Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 18. North America CAR T-Cell Therapy Market Share by Country (2021–2032)
 Figure 19. United States CAR T-Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 20. Canada CAR T-Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 21. Europe CAR T-Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 22. Europe CAR T-Cell Therapy Market Share by Country (2021–2032)
 Figure 23. Germany CAR T-Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 24. France CAR T-Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 25. U.K. CAR T-Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 26. Italy CAR T-Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 27. Russia CAR T-Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 28. Ireland CAR T-Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 29. Asia-Pacific CAR T-Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 30. Asia-Pacific CAR T-Cell Therapy Market Share by Region (2021–2032)
 Figure 31. China CAR T-Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 32. Japan CAR T-Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 33. South Korea CAR T-Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 34. Southeast Asia CAR T-Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 35. India CAR T-Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 36. Australia & New Zealand CAR T-Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 37. Latin America CAR T-Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 38. Latin America CAR T-Cell Therapy Market Share by Country (2021–2032)
 Figure 39. Mexico CAR T-Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 40. Brazil CAR T-Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 41. Middle East & Africa CAR T-Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 42. Middle East & Africa CAR T-Cell Therapy Market Share by Country (2021–2032)
 Figure 43. Israel CAR T-Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 44. Saudi Arabia CAR T-Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 45. UAE CAR T-Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 46. Novartis Revenue Growth Rate in CAR T-Cell Therapy Business (2021–2026)
 Figure 47. Gilead Sciences Revenue Growth Rate in CAR T-Cell Therapy Business (2021–2026)
 Figure 48. Bristol-Myers Squibb Revenue Growth Rate in CAR T-Cell Therapy Business (2021–2026)
 Figure 49. J & J Revenue Growth Rate in CAR T-Cell Therapy Business (2021–2026)
 Figure 50. JW Therapeutics Revenue Growth Rate in CAR T-Cell Therapy Business (2021–2026)
 Figure 51. FOSUNKite Revenue Growth Rate in CAR T-Cell Therapy Business (2021–2026)
 Figure 52. CARsgen Therapeutics (Pipeline) Revenue Growth Rate in CAR T-Cell Therapy Business (2021–2026)
 Figure 53. Autolus Therapeutics(Pipeline) Revenue Growth Rate in CAR T-Cell Therapy Business (2021–2026)
 Figure 54. Sorrento Therapeutics(Pipeline) Revenue Growth Rate in CAR T-Cell Therapy Business (2021–2026)
 Figure 55. Mustang Bio(Pipeline) Revenue Growth Rate in CAR T-Cell Therapy Business (2021–2026)
 Figure 56. Bluebird Bio(Pipeline) Revenue Growth Rate in CAR T-Cell Therapy Business (2021–2026)
 Figure 57. Cellectis(Pipeline) Revenue Growth Rate in CAR T-Cell Therapy Business (2021–2026)
 Figure 58. Allogene Therapeutics(Pipeline) Revenue Growth Rate in CAR T-Cell Therapy Business (2021–2026)
 Figure 59. Celyad(Pipeline) Revenue Growth Rate in CAR T-Cell Therapy Business (2021–2026)
 Figure 60. Bottom-up and Top-down Approaches for This Report
 Figure 61. Data Triangulation
 Figure 62. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Leap India

SIMILAR REPORTS

Global CAR T Cell Service Market Research Report 2024
Global CAR T Therapy for Hematological Cancer Market Research Report 2024
Global CAR T cell Therapy Drug Market Research Report 2025
Global CAR T Cell Therapy Agents Market Research Report 2025
Global Autologous CAR T Cell Therapy Market Research Report 2024
Global Drug based on CAR T Cell Market Research Report 2025
Global Drugs Based on CAR T cell Market Research Report 2025
CAR T Cellular Immunotherapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
CAR T Cell Based Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global CAR T Cell Development Service Market Research Report 2024
Cancer Drug based on CAR T Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global CD19 targeted CAR T Cell Therapy Market Research Report 2024
Global CAR T Cell Manufacturing Service Market Research Report 2024
Global T Cell Immunotherapy Market Research Report 2025
Global CAR T Cell Immunotherapy Market Insights Forecast to 2030
Global BCMA targeted CAR T Cell Therapy Market Research Report 2025
Global Gene Modifying Immunotherapy for Blood Cancer Market Insights Forecast to 2030
Chimeric Antigen Receptor CAR T Cell Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global TCR T Cellular Immunotherapy Market Research Report 2024
Global Chimeric Antigen Receptor T Cell Therapy Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions